A compound originally developed as a cancer treatment may hold promise for treating polycystic kidney disease (ADPKD), which affects more than half a million Americans and can lead to kidney ...
Autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease, can lead to kidney enlargement and eventual loss of function. The disease affects more than 12 ...
Polycystic kidney disease (PKD) is a debilitating hereditary condition in which fluid-filled sacs form and proliferate in the kidneys. Over time, the painful, growing cysts rob the organs of their ...
Polycystic kidney disease (PKD) is a debilitating hereditary condition in which fluid-filled sacs form and proliferate in the kidneys. Over time, the painful, growing cysts rob the organs of their ...
Credit: Getty Images The inaugural ADPKD guideline introduces new ADPKD nomenclature and offers updated recommendations on therapies to slow disease progression. The inaugural ADPKD guideline from ...
MIT researchers including Robert Croy (left) and Bogdan Fedeles have discovered that a drug they originally developed as a potential cancer treatment may also hold promise in treating autosomal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results